Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Autologous tumor cell-derived microparticle-based targeted chemotherapy in lung cancer patients with malignant pleural effusion.

Guo M, Wu F, Hu G, Chen L, Xu J, Xu P, Wang X, Li Y, Liu S, Zhang S, Huang Q, Fan J, Lv Z, Zhou M, Duan L, Liao T, Yang G, Tang K, Liu B, Liao X, Tao X, Jin Y.

Sci Transl Med. 2019 Jan 9;11(474). pii: eaat5690. doi: 10.1126/scitranslmed.aat5690.

PMID:
30626714
3.
4.

Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion.

Stathopoulos GT, Sherrill TP, Karabela SP, Goleniewska K, Kalomenidis I, Roussos C, Fingleton B, Yull FE, Peebles RS Jr, Blackwell TS.

Am J Respir Crit Care Med. 2010 Nov 15;182(10):1273-81. doi: 10.1164/rccm.201001-0001OC. Epub 2010 Jul 1.

5.

Impaired T cell function in malignant pleural effusion is caused by TGF-β derived predominantly from macrophages.

Li L, Yang L, Wang L, Wang F, Zhang Z, Li J, Yue D, Chen X, Ping Y, Huang L, Zhang B, Zhang Y.

Int J Cancer. 2016 Nov 15;139(10):2261-9. doi: 10.1002/ijc.30289. Epub 2016 Aug 6.

6.

Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer.

Ren S, Terman DS, Bohach G, Silvers A, Hansen C, Colt H, Sahn SA.

Chest. 2004 Nov;126(5):1529-39. Erratum in: Chest. 2011 Sep;140(3):835.

PMID:
15539723
7.

Interleukin-2 reverses CD8(+) T cell exhaustion in clinical malignant pleural effusion of lung cancer.

Hu CY, Zhang YH, Wang T, Chen L, Gong ZH, Wan YS, Li QJ, Li YS, Zhu B.

Clin Exp Immunol. 2016 Oct;186(1):106-14. doi: 10.1111/cei.12845. Epub 2016 Aug 23.

8.

Secreted phosphoprotein-1 directly provokes vascular leakage to foster malignant pleural effusion.

Psallidas I, Stathopoulos GT, Maniatis NA, Magkouta S, Moschos C, Karabela SP, Kollintza A, Simoes DC, Kardara M, Vassiliou S, Papiris SA, Roussos C, Kalomenidis I.

Oncogene. 2013 Jan 24;32(4):528-35. doi: 10.1038/onc.2012.57. Epub 2012 Feb 27.

PMID:
22370646
9.

A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion.

Stathopoulos GT, Psallidas I, Moustaki A, Moschos C, Kollintza A, Karabela S, Porfyridis I, Vassiliou S, Karatza M, Zhou Z, Joo M, Blackwell TS, Roussos C, Graf D, Kalomenidis I.

J Natl Cancer Inst. 2008 Oct 15;100(20):1464-76. doi: 10.1093/jnci/djn325. Epub 2008 Oct 7.

PMID:
18840818
10.

Beneficial impact of CCL2 and CCL12 neutralization on experimental malignant pleural effusion.

Marazioti A, Kairi CA, Spella M, Giannou AD, Magkouta S, Giopanou I, Papaleonidopoulos V, Kalomenidis I, Snyder LA, Kardamakis D, Stathopoulos GT.

PLoS One. 2013 Aug 14;8(8):e71207. doi: 10.1371/journal.pone.0071207. eCollection 2013.

11.

CD163+CD14+ macrophages, a potential immune biomarker for malignant pleural effusion.

Wang F, Yang L, Gao Q, Huang L, Wang L, Wang J, Wang S, Zhang B, Zhang Y.

Cancer Immunol Immunother. 2015 Aug;64(8):965-76. doi: 10.1007/s00262-015-1701-9. Epub 2015 May 6.

PMID:
25944005
12.

Structural basis for hyperpermeability of tumor vessels in advanced lung adenocarcinoma complicated by pleural effusion.

Damianovich M, Hout Siloni G, Barshack I, Simansky DA, Kidron D, Dar E, Avivi C, Onn A.

Clin Lung Cancer. 2013 Nov;14(6):688-98. doi: 10.1016/j.cllc.2013.06.007. Epub 2013 Aug 6.

PMID:
23931900
13.

Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study.

Psallidas I, Karabela SP, Moschos C, Sherrill TP, Kollintza A, Magkouta S, Theodoropoulou P, Roussos C, Blackwell TS, Kalomenidis I, Stathopoulos GT.

Mol Cancer. 2010 Mar 10;9:56. doi: 10.1186/1476-4598-9-56.

14.

Interplay of Th1 and Th17 cells in murine models of malignant pleural effusion.

Lin H, Tong ZH, Xu QQ, Wu XZ, Wang XJ, Jin XG, Ma WL, Cheng X, Zhou Q, Shi HZ.

Am J Respir Crit Care Med. 2014 Mar 15;189(6):697-706. doi: 10.1164/rccm.201310-1776OC.

PMID:
24410406
15.

Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion.

Du N, Li X, Li F, Zhao H, Fan Z, Ma J, Fu Y, Kang H.

Oncol Rep. 2013 Jun;29(6):2332-40. doi: 10.3892/or.2013.2349. Epub 2013 Mar 15.

PMID:
23525453
16.

Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion.

Tao H, Meng Q, Li M, Shi L, Tang J, Liu Z.

Thorac Cancer. 2018 Feb;9(2):298-304. doi: 10.1111/1759-7714.12582. Epub 2018 Jan 3.

17.

Tumor necrosis factor-alpha promotes malignant pleural effusion.

Stathopoulos GT, Kollintza A, Moschos C, Psallidas I, Sherrill TP, Pitsinos EN, Vassiliou S, Karatza M, Papiris SA, Graf D, Orphanidou D, Light RW, Roussos C, Blackwell TS, Kalomenidis I.

Cancer Res. 2007 Oct 15;67(20):9825-34.

18.

Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity.

Roscilli G, De Vitis C, Ferrara FF, Noto A, Cherubini E, Ricci A, Mariotta S, Giarnieri E, Giovagnoli MR, Torrisi MR, Bergantino F, Costantini S, Fenizia F, Lambiase M, Aurisicchio L, Normanno N, Ciliberto G, Mancini R.

J Transl Med. 2016 Feb 29;14:61. doi: 10.1186/s12967-016-0816-x.

19.

Establishment of a malignant pleural effusion mouse model with lewis lung carcinoma cell lines expressing enhanced green fluorescent protein.

Ma X, Sun Y, Wang S, Yang Z, Song Y.

Transl Lung Cancer Res. 2012 Sep;1(3):170-8. doi: 10.3978/j.issn.2218-6751.2012.07.01.

20.

[Treatment of pleural effusion caused by lung carcinoma with circular intrapleural hyperthermic perfusion and its mechanism].

Kang M, Zhou L, Lin P.

Zhonghua Yi Xue Za Zhi. 2001 Oct;81(19):1176-9. Chinese.

PMID:
11769704

Supplemental Content

Support Center